For the treatment of relapsed or refractory multiple myeloma, clinical trials with CAR-NK cells that express an anti-BCMA (B-cell maturation antigen highly expressed on myeloma cells) construct, together with chemotherapy, are underway (NCT03940833, NCT05008536). Here, TNFRSF17 is linked to plasma cell myeloma.